Madhi SA, Polack FP, Piedra PA, Munoz FM, Trenholme AA, Simões EAF, Swamy GK, Agrawal S, Ahmed K, August A, Baqui AH, Calvert A, Chen J, Cho I, Cotton MF, Cutland CL, Englund JA, Fix A, Gonik B, Hammitt L, Heath PT, de Jesus JN, Jones CE, Khalil A, Kimberlin DW, Libster R, Llapur CJ, Lucero M, Pérez Marc G, Marshall HS, Masenya MS, Martinón‐Torres F, Meece JK, Nolan TM, Osman A, Perrett KP, Plested JS, Richmond PC, Snape MD, Shakib JH, Shinde V, Stoney T, Thomas DN, Tita AT, Varner MW, Vatish M, Vrbicky K, Wen J, Zaman K, Zar HJ, Glenn GM, and Fries LF, for the Prepare Study Group
Novavax shows an almost 40% reduction in medically significant RSV-associated LRTIs, in their phase 3 randomized controlled trial with the support of the Bill and Melinda Gates foundation. They recruited healthy pregnant women, at 28 weeks through 36 weeks of gestation, before the start of the RSV season. They were randomly assigned with an overall 2:1 ratio to receive a RSV fusion (F) protein nanoparticle vaccine or placebo. In total, 4636 women were enrolled. The vaccine was safe, with a percentage of infants with a RSV-associated, medically significant lower respiratory tract infection of 1.5% in the vaccine group versus 2.4% in the placebo group (vaccine efficacy was 39.4%). This difference was not sufficient according to FDA-required prespecified criteria of vaccine efficacy. Interestingly, in the vaccine group RSV-related hospitalisations and all-cause pneumonia were significantly reduced by 44% and approx. 50%, respectively. Adding to that, a higher vaccine efficacy was seen in low- or middle-income countries (LMIC), where prevention of RSV is most needed. An explanation for the differential effect in high income countries versus LMIC is still being sought. For now, the faith of the first safe and efficacious RSV vaccine remains uncertain.
This summary is written by Roy Zuurbier
Sesterhenn F, Yang C, Bonet J, Cramer JT, Wen X, Wang Y, Chiang CI, Abriata LA, Kucharska I, Castoro G, Vollers SS, Galloux M, Dheilly E, Rosset S, Corthésy P, Georgeon S, Villard M, Richard CA, Descamps D, Delgado T, Oricchio E,
Rameix-Welti MA, Más V, Ervin S, Eléouët JF, Riffault S, Bates JT, Julien JP, Li Y, Jardetzky T, Krey T, Correia BE
You can make your own computationally designed protein-based vaccine using TopoBuilder, a protein design algorithm. Sesterhenn and colleagues made a stable RSV F protein in prefusion conformation. They showed that this engineered protein was immunogenic in mice and induced neutralizing antibodies in non-human primates using prime-boost schemes. Neutralizing antibody levels was at least as high as palivizumab concentrations known to be protective. The vaccine may now be further developed. Obviously, this technology which allows generating vaccines against other pathogens has a promising future.
Mueller S, Stauft CB, Kalkeri R, Koidei F, Kushnir A, Tasker S, Coleman JR.
A novel codon-deoptimized RSV vaccine protected African Green Monkeys against viral replication and induced neutralizing antibodies as well as cellular IFNg response against RSV. Deoptimized vaccines are generated in vitro with the aim to impair replication in human cells through multiple synonymous codon changes. The idea is that the amino acid order is not changed. The vaccine was tested in African Green Monkeys challenged with RSV A2. Replication of MinL4.0 was decreased a 100-fold compared to wild-type A2. Anectodally, the investigators report that there was one animal with preexistent neutralizing antibodies who still responded to MinL4.0 suggesting the vaccine can be used in exposed individuals. The vaccine has been developed by Codagenix Inc with support of NIAID. The vaccine will now be tested as a mucosal vaccine in humans.
Cicconi P, Jones C, Sarkar E, Silva-Reyes L, Klenerman P, de Lara C, Hutchings C, Moris P, Janssens M, Lisette LA, Picciolato M, Leach A, Gonzalez-Lopez A, Dieussaert I and D.Snap M.
This paper presents the results of a novel chimpanzee-derived replication-deficient adenoviral vector vaccine against RSV (ChAd155-RSV), based on 3 RSV viral proteins including F (fusion), N(nucleocapsid), and M2-1 (antitermination). Although the intended use is in the infant population, this phase 1 first-in-human study aimed to investigate safety, reactogenicity, and immunogenicity of ChAd155-RSV in healthy adults aged 18–45 years. Adenoviral vector vaccines have shown to be able to elicit long-term cellular and humoral immune responses and are efficient in delivering foreign antigens into host cells. Although potent, the immune response elicited by this type of vaccine is dependent on the recipient’s immune status. While ChAd155-RSV antibodies could decrease the overall efficacy of the vaccine and preexisting anti-RSV NAb could mask the humoral response, a vaccine response was seen in about 60% of the high-dosage group and 20% in the low-dosage group. The key value of this study is confirmation of the ability of viral vector vaccines to intrinsically promote a combined cellular and humoral immune response to one of the most important pathogens in infancy. With low levels of preexisting antibodies against both RSV and adenovirus in the pediatric population, the potency of these vaccines in eliciting a vaccine response may be higher compared to the adult population.
Uusitupa E, Waris M, Heikkinen T.
Over the past years results on the associations between RSV loads and severe manifestations of the RSV illness were contradictory. Nevertheless, association between viral load and severity of illness in contributive for the use of antivirals in RSV disease. Heikkinen and colleagues conducted a prospective cohort study of respiratory outpatient naturally infected children. During each episode of respiratory illness, children were clinically examined, nasal swaps for virus sampling were taken and daily symptoms were recorded. In 201 new onset RSV infections, Heikkinen and colleagues show that children with higher viral load had significantly longer durations of respiratory compared to children with lower viral load. The findings in this largest outpatient study so far on this topic, support the concept that viral load drives the severity of RSV disease in children. RSV infected children might benefit of the reduction of RSV viral load by RSV antivirals.
Neutrophil-endothelial interactions in respiratory syncytial virus bronchiolitis, a potential for prediction of severity of disease?
Amadu Juliana, Rens Zonneveld, Frans B. Plötz, Matthijs van Meurs, Jan Wilsschute
The exact molecular mechanism of neutrophil migration into the airway in respiratorysyncytial virus (RSV) infection is little studied.This paper reviews the to date evidence of activation of endothelial cells and neutrophils, interaction of neutrophils with endothelial cells and migration across endothelial cells in Respiratory Syncytial Virus (RSV) infection. In addition, the possible clinical relevance of systemically measurable soluble endothelial adhesion molecules is reviewed. The limited number of studies showed increased levels of soluble cell adhesion molecules (CAMs) in RSV LRTI but could not assess associations of soluble CAM levels with clinical outcomes.
Finally, this paper describes the to date evidence for the deleterious effects of neutrophils in RSV infection. Juliana at al. describe how massive influx of neutrophils also causes damage and consequently more symptoms. Assuming that there is a massive efflux of neutrophils into the lungs with subsequent endothelial and epithelial damage, and that this is the basis for severe disease, the authors propose larger studies and simultaneous measurements of markers of neutrophil and endothelial activation and integrity for prediction of severe disease.
A phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients
Chemaly RF, Dadwal SS, Bergeron A, Ljungman P, Kim YJ, Cheng GS, Pipavath SN, Limaye AP, Blanchard E, Winston DJ, Stiff PJ, Zuckerman T, Lachance S, Rahav G, Small CB, Mullane KM, Patron RL, Lee DG, Hirsch HH, Waghmare A, McKevitt M, Jordan R, Guo Y, German P, Porter DP, Gossage DL, Watkins TR, Marty FM, Chien JW, Boeckh M.
RSV treatment options are currently limited, and various RSV antivirals are currently under clinical development. Presatovir (GS-5806) is an oral RSV fusion inhibitor with potent and selective anti-RSV activity in vitro and a terminal half-life of ~34 hours. During a human challenge study, presatovir reduced RSV viral load and severity of clinical disease. A phase 2, randomized, double-blind, placebo-controlled trial was conducted to assess the safety, tolerability and efficacy of presatovir among HCT patients with RSV upper respiratory tract infection (URTI). In total, 189 patients with diagnosed RSV URTI ≤6 days and without new abnormalities on a chest X-ray <48 hours before start of study treatment were recruited. Patients received presatovir 2000 mg (4 x 50 mg tablets) or placebo orally or by nasogastric tube on days 1, 5, 9, 13, and 17, and were followed through day 28. Presatovir had a favorable safety profile, but the co-primary endpoints (time-weighted average change in nasal viral load between day 1-9 and proportion of patients that developed lower respiratory tract complications between day 1-28) were not achieved. However, in a post-hoc exploratory analysis, significantly more patients with lymphopenia (<200 cells/µL) developed lower respiratory tract complications in the placebo group. This interesting finding suggests that antiviral treatment might be beneficial in RSV URTI patients with most severe T-cell defect to prevent deterioration to severe lower respiratory tract infection (LRTI).
This summary is written by Yvette Lowensteyn
Ruth A. Karron, Cindy Luongo, Jocelyn San Mateo, Kimberli Wanionek, Peter L. Collins, Ursula J. Buchholz, and the RSVPed Team
The RSV/NS2/1313/I1314L is an intranasal vaccine that contains two attenuating elements in the RSV strain: deletion of the NS2 gene and deletion of the codon 1313. The deletions are stabilized with the substitution of isoleucine at codon 1314. This vaccine induced an immunogenic response in nonhuman primates. A phase 1 double-blind, randomized, placebo-controlled trial was conducted at the Center for Immunization Research (CIR) between 2013 and 2018 in RSV-seronegative and RSV-seropositive children aged 12-59 months. RSV-seronegative children received a single dose of 10 5 or 10 6 PFU and RSV-seropositive children received a single dose of 10 6 PFU. The authors demonstrated that none of the RSV-seropositive children had a ≥4-fold rise in RSV F serum IgG titer. By contrast, 53% of RSV-seronegative children who received 10 5 PFU, developed RSV neutralizing antibodies and F
IgG responses. In RSV-seronegative children receiving 10 6 PFU, even 80% developed RSV neutralizing antibodies and a similar rise in RSV-F IgG antibodies. This indicates that the RSV vaccine is a proper and genetically stable candidate in RSV-seronegative children, which deserves further clinical evaluation in seronegative children.
This review was written by Safia Laqqa under the supervision of Louis Bont
Tang A, Chen Z, Cox KS, Su HP, Callahan C, Fridman A, Zhang L, Patel SB, Cejas PJ, Swoyer R, Touch S, Citron MP, Govindarajan D, Luo B, Eddins M, Reid JC, Soisson SM, Galli J, Wang D, Wen Z, Heidecker GW, Casimiro DR, DiStefano DJ & Vora KA.
RB1 is a human monoclonal antibody that binds to site IV of the RSV F glycoprotein and is 50 times more potent than palivizumab. Tang and colleagues describe the crystal structure of RB1 and how it recognizes both RSV preF and RSV postF. They show that natural resistance occurs in less than one percent of more than 3000 isolates available in GenBank. The authors also demonstrate excellent neutralization of clinical isolates. RB1 is different from MEDI8897 because it binds to another site of RSV F, it recognized both preF and postF and appears to have a lower frequency of natural resistant clinical isolates. MK-1654 is an extended half-life version of RB1 (half-life 70-85 days) by introduction of a YTE mutation of the Fc part of the antibody. Merck is aims to develop MK-1654 for use in preterm as well as term children. The results of a phase 1-2 trial are expected in 2022 (www.clinicaltrials.gov). This paper shows that MK-1654 as the potential to be developed as a universal RSV passive immunization solution.
Crank MC, Ruckwardt TJ, Chen M, Morabito1 KM, Phung E, Costner PJ, Holman LA, Hickman SP, Berkowitz NM, Gordon IJ, Yamshchikov GV, Gaudinski MR, Kumar A, Chang LA, Moin SM, Hill JP, DiPiazza AT, Schwartz RM, Kueltzo1 L, Cooper JW, Chen P, Stein JA, Carlton1 K, Gall JG, Nason MC, Kwong PD, Chen1 GL, Mascola JR,McLellan JS, Ledgerwood JE, Graham BS, the VRC 317 Study Team
This RSV subunit vaccine has smoothly passed the first hurdle in clinical development. DS-Cav1 is stabilized trimer of the prefusion conformation of the RSV-F protein. The vaccine was clinically evaluated by the same researchers of the Vaccine Research Center (VRC) of the Nation Institute of Health (NIH) only a few years after demonstrating the existence of the prefusion and postfusion RSV-F variants. Immunogenicity of this apparently safe vaccine was tested in a diverse group of 40 healthy adults up to 12 weeks after vaccination. Remarkably, the vaccine resulted in an increase in neutralization that was larger than the increase in binding to RSV F. Twelve weeks after vaccination, neutralization of RSV A was still increased 5 to 10-fold, while a 3 to 5-fold increase in RSV B neutralization was observed. The boost of neutralization was mediated by antibodies against preF and shared pre/post F epitopes, but not by antibodies against epitopes only present at postF. Using preF and postF probes, the authors show that the vaccine elicits a boost in memory preF B-cells, but not postF B-cells. Taken together, DS-Cav1 shows superiority to previous subunit vaccines by inducing higher levels of neutralizing antibodies with a relatively low induction of non-neutralizing antibodies.